{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-23-000074","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.179772+00:00","generated_at":"2026-06-15T13:47:08.589128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Denali Q1 net loss widens to $109.8M; Biogen licenses ATV:Abeta, DNL310 positive data","bullets":["Net loss $109.8M vs $65.2M YoY; collaboration revenue $35.1M vs $42.1M.","R&D expenses rose to $128.8M from $86.1M; cash & securities $1.29B at March 31.","Biogen exercised option to license ATV:Abeta; Denali receives option payment and milestones.","DNL310 Phase 1/2 interim data showed improved behavior/cognition; COMPASS study enrolling.","Triggered $30M contingent consideration for F-star Gamma; $10M milestone from Takeda for DNL593."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-23-000074","json":"https://secwatch.observer/filing/0001714899-23-000074.json","markdown":"https://secwatch.observer/filing/0001714899-23-000074.md","text":"https://secwatch.observer/filing/0001714899-23-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000074/0001714899-23-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000074/dnli-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:47:08.589128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"debe1c1086d03c61899c11e7b83087fc9f19f575","claim":"Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"Denali Therapeutics Inc. (the \"Company\") issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000074/0001714899-23-000074-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}